AMR Action Fund announces more investments to combat antibiotic resistance
The recipients are Vedanta Biosciences, whose lead candidate is a microbiome-directed C difficile therapy, and diagnostics company Pattern Bioscience for rapid bacterial susceptibility tests.
Source: umn.edu